ΙΑΤΡΙΚΕΣ ΠΛΗΡΟΦΟΡΙΕΣ:

Διάγνωση - Ιστορικό

2001 Biopsy: confirmation of malignancy (Adeno-Ca of the prostate, Gleason score 5 (2+3) (no report submitted)

2001 2x Hypethermia as well as diverse alternative treatments

2018-21 Initiation of anti-androgen, Bicalutamide (initially 50 mg then 150 mg)

2021 Gradual PSA despite Bicalutamide

05/22 Ga68-PSMA PET/CT (Wiesbaden, Germany): highly PSMA expressing prostatic malignancy with SV invasion, and ECE with at least contact to the anterior rectal wall. Highly PSMA positive pelvic and retroperitoneal LNs, supradiaphragmatic LNs, and multiple bone lesions (Th3, Th12, 7th rib, L5)

05/22 MRI Pelvis: Prostate volume 43cc. PI-RADS V lesion within the posterior PZ extending just above the apex of the prostate.

11/22 PSA 248 ng/ml

11/22 ADT initiation with Goserelin 10.8 mg and Enzalutamide (GOC)

12/22 SBRT of T3 spine 30 Gy in 10 Gy

05/23 PSA 80 ng/ml under sufficient testosteron suppresion

08/23 PSA 128 ng/ml under sufficient testosteron suppresion

08/23 PSMA-PET/CT: SD and CR in the prostate and LNs, mixed response in bones with up to 5 bone mets in progress